News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Baynes Roy D.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/05/2023 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Natera, Inc.|
Txns:
| Granted 2,750 shares
@ $0
Granted 4,255 options to buy
@ $48.66, valued at
$207k
|
|
| 05/26/2023 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Natera, Inc.|
Txns:
| Exercised 3,534 restricted stock units
@ $0 |
|
| 05/19/2023 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/18/2023 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Natera, Inc.|
Txns:
| Granted 312 shares
@ $40.01, valued at
$12.5k
|
|
| 10/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/02/2022 |
4/A
| Baynes Roy D. (Director) has filed a Form 4 on Natera, Inc.|
Txns:
| Granted 344 shares
@ $0 |
|
| 07/12/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/12/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/09/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/18/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/11/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/17/2020 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Atara Biotherapeutics, Inc.|
Txns:
| Granted 8,000 shares
@ $0
Granted 24,500 options to buy
@ $10.54, valued at
$258.2k
|
|
| 06/16/2020 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Natera, Inc.|
Txns:
| Granted 2,856 restricted stock units
@ $0
Granted 5,712 options to buy
@ $40.93, valued at
$233.8k
|
|
| 05/19/2020 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Retrophin, Inc.|
Txns:
| Granted 3,000 shares
@ $0
Granted 9,000 options to buy
@ $15.43, valued at
$138.9k
|
|
| 07/01/2019 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Atara Biotherapeutics, Inc.|
Txns:
| Granted 4,000 shares
@ $0
Granted 13,000 options to buy
@ $20.25, valued at
$263.3k
|
|
| 05/29/2019 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Natera, Inc.|
Txns:
| Granted 22,000 options to buy
@ $22.83, valued at
$502.3k
|
|
| 05/10/2019 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Retrophin, Inc.|
Txns:
| Granted 2,000 shares
@ $0
Granted 8,000 options to buy
@ $17.94, valued at
$143.5k
|
|
| 09/18/2018 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Natera, Inc.|
Txns:
| Granted 16,530 options to buy
@ $24.42, valued at
$403.7k
|
|
| 09/12/2018 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Atara Biotherapeutics, Inc.|
Txns:
| Granted 16,500 options to buy
@ $41.05, valued at
$677.3k
|
|
| 09/12/2018 |
3
| Baynes Roy D. (Director) has filed a Form 3 on Atara Biotherapeutics, Inc. |
| 08/02/2018 |
3
| Baynes Roy D. (Director) has filed a Form 3 on Natera, Inc. |
| 05/11/2018 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Retrophin, Inc.|
Txns:
| Granted 2,500 shares
@ $0
Granted 10,000 options to buy
@ $26.52, valued at
$265.2k
|
|
| 05/18/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/26/2016 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Retrophin, Inc.|
Txns:
| Granted 4,000 shares
@ $0
Granted 16,000 options to buy
@ $17.5, valued at
$280k
|
|
| 07/26/2016 |
3
| Baynes Roy D. (Director) has filed a Form 3 on Retrophin, Inc. |
|
|